Terms: = Breast cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
55 results:
1. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer.
Nelson BE; Saleem S; Damodaran S; Somaiah N; Piha-Paul S; Moore JA; Yilmaz B; Ogbonna D; Karp DD; Dumbrava E; Tsimberidou AM; Hong DS; Rodon Ahnert J; Milton DR; Zheng X; Booser DJ; Ibrahim NK; Conley AP; Bhosale P; Rojas Hernandez CM; Tripathy D; Naing A; Meric-Bernstam F
Cancer; 2023 Jul; 129(14):2201-2213. PubMed ID: 37016732
[TBL] [Abstract] [Full Text] [Related]
2. Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC; Slomovitz B; Coleman RL; Pothuri B
Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
[TBL] [Abstract] [Full Text] [Related]
3. KPT-330 and Y219 exert a synergistic antitumor effect in triple-negative breast cancer through inhibiting NF-κB signaling.
Wen T; Geng M; Bai E; Wang X; Miao H; Chen Z; Zhou H; Wang J; Shi J; Zhang Y; Lei M; Zhu Y
FEBS Open Bio; 2023 Apr; 13(4):751-762. PubMed ID: 36847599
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract] [Full Text] [Related]
5. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44
Liu C; Zhang Y; Gao J; Zhang Q; Sun L; Ma Q; Qiao X; Li X; Liu J; Bu J; Zhang Z; Han L; Zhao D; Yang Y
Drug Resist Updat; 2023 Jan; 66():100903. PubMed ID: 36463808
[TBL] [Abstract] [Full Text] [Related]
6. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Westin SN; Fu S; Tsimberidou A; Piha-Paul S; Akhmedzhanov F; Yilmaz B; McQuinn L; Brink AL; Gong J; Leung CH; Lin H; Hong DS; Pant S; Carter B; Jazaeri A; Gershenson D; Sood AK; Coleman RL; Shah J; Meric-Bernstam F; Naing A
Gynecol Oncol; 2023 Jan; 168():76-82. PubMed ID: 36423446
[TBL] [Abstract] [Full Text] [Related]
7. The efficacy of selinexor (KPT-330), an xpo1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
8. Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.
Shi Y; Xu S; Li S
Mol Cell Endocrinol; 2022 Apr; 545():111558. PubMed ID: 35033575
[TBL] [Abstract] [Full Text] [Related]
9. De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens.
Weiskittel TM; Ung CY; Correia C; Zhang C; Li H
Genome Res; 2022 Jan; 32(1):124-134. PubMed ID: 34876496
[TBL] [Abstract] [Full Text] [Related]
10. Discovery and biological evaluation of a small-molecule inhibitor of crm1 that suppresses the growth of triple-negative breast cancer cells.
Gao J; Chu P; Liu C; Sun Z; Liu Q; Yang Y
Traffic; 2021 Jul; 22(7):221-229. PubMed ID: 34021516
[TBL] [Abstract] [Full Text] [Related]
11. IFI27/ISG12 Downregulates Estrogen Receptor α Transactivation by Facilitating Its Interaction With crm1/xpo1 in breast cancer Cells.
Cervantes-Badillo MG; Paredes-Villa A; Gómez-Romero V; Cervantes-Roldán R; Arias-Romero LE; Villamar-Cruz O; González-Montiel M; Barrios-García T; Cabrera-Quintero AJ; Rodríguez-Gómez G; Cancino-Villeda L; Zentella-Dehesa A; León-Del-Río A
Front Endocrinol (Lausanne); 2020; 11():568375. PubMed ID: 33117284
[TBL] [Abstract] [Full Text] [Related]
12. Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody.
Martini S; Figini M; Croce A; Frigerio B; Pennati M; Gianni AM; De Marco C; Daidone MG; Argueta C; Landesman Y; Zaffaroni N; Satta A
Cells; 2020 Oct; 9(10):. PubMed ID: 33023194
[TBL] [Abstract] [Full Text] [Related]
13. Budlein A methylacrylate demonstrates potent activity against triple-negative breast cancer by targeting IκBα kinase and exportin-1.
Wang XZ; Feng Y; Han YF; Bian Y; Liang J; Wen HM; Wu H
Toxicol Appl Pharmacol; 2020 Dec; 408():115263. PubMed ID: 33022283
[TBL] [Abstract] [Full Text] [Related]
14. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway.
Seervi M; Sumi S; Chandrasekharan A; Sharma AK; SanthoshKumar TR
Cell Oncol (Dordr); 2019 Oct; 42(5):645-661. PubMed ID: 31147963
[TBL] [Abstract] [Full Text] [Related]
15. Differential expression and molecular interactions of chromosome region maintenance 1 and calreticulin exportins in breast cancer cells.
Cruz-Ramos E; Sandoval-Hernández A; Tecalco-Cruz AC
J Steroid Biochem Mol Biol; 2019 Jan; 185():7-16. PubMed ID: 29981820
[TBL] [Abstract] [Full Text] [Related]
16. Stress-activated MAPKs and crm1 regulate the subcellular localization of Net1A to control cell motility and invasion.
Ulu A; Oh W; Zuo Y; Frost JA
J Cell Sci; 2018 Feb; 131(3):. PubMed ID: 29361525
[TBL] [Abstract] [Full Text] [Related]
17. Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through crm1-mediated p62/SQSTM1 accumulation and AMPK activation.
Wang H; Wang F; Wu S; Liu Z; Li T; Mao L; Zhang J; Li C; Liu C; Yang Y
Chem Biol Interact; 2018 Feb; 281():11-23. PubMed ID: 29247643
[TBL] [Abstract] [Full Text] [Related]
18. SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase.
Knittle AM; Helkkula M; Johnson MS; Sundvall M; Elenius K
J Biol Chem; 2017 Dec; 292(48):19890-19904. PubMed ID: 28974580
[TBL] [Abstract] [Full Text] [Related]
19. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
[TBL] [Abstract] [Full Text] [Related]
20. cancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motif.
Pauty J; Couturier AM; Rodrigue A; Caron MC; Coulombe Y; Dellaire G; Masson JY
Nucleic Acids Res; 2017 Mar; 45(5):2644-2657. PubMed ID: 28158555
[TBL] [Abstract] [Full Text] [Related]
[Next]
